Taken together, our results suggest that the topical application of Hsp90 inhibitors offers greater therapeutic benefits due to a reduced risk of systemic side effects and therefore may be useful for controlling AD and possibly other related inflammatory skin diseases. The gene discussed is HSP90AB1; the disease is Alzheimer disease.